加载中
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
前收盘价
US$31.10
−US$0.02 · -0.06%
盘中时间采用ET。市场数据可能有所延迟。
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
日内区间
当前US$31.10
52周区间
当前US$31.10
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
32
偏贵
情绪
58
多空交织
风险
27
中等风险
动量
84
强势上行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
日内区间
当前US$31.10
52周区间
当前US$31.10
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1.24亿 EUR | 9856.35万 EUR | 6557.5万 EUR | 5737.56万 EUR | 3578.92万 EUR |
| 销售、一般及管理费用 | 4534.46万 EUR | 4712.46万 EUR | 3133.86万 EUR | 2933.9万 EUR | 1834.95万 EUR |
| 营业费用 | 1.7亿 EUR | 1.46亿 EUR | 9691.36万 EUR | 8671.46万 EUR | 5413.86万 EUR |
| 利息收入 | — | 546.9万 EUR | — | 16.11 EUR | 267.51 EUR |
| 利息支出 | — | — | — | 1.61万 EUR | 27.82万 EUR |
| 折旧和摊销 | 41.84万 EUR | 26.96万 EUR | 25.76万 EUR | 15.29万 EUR | 7.74万 EUR |
| 营业利润 | −1.7亿 EUR | −1.46亿 EUR | −9691.36万 EUR | −8671.46万 EUR | −5413.86万 EUR |
| 净利润 | −1.76亿 EUR | −1.34亿 EUR | −1.01亿 EUR | −7633.26万 EUR | −4273.08万 EUR |
公司数据更新于 2026年10月11日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB797.37万0.08%108.2亿 USD0.44%US$206.49+3.00%
iShares Core MSCI EAFE ETFIEFA405.09万0.00%1894.71亿 USD0.07%US$96.52+0.68%
iShares MSCI EAFE Small-Cap ETFSCZ261.19万0.02%128.85亿 USD0.40%US$83.93+0.82%
iShares MSCI Netherlands ETFEWN164.37万0.23%7.02亿 USD0.50%US$66.64+0.70%
Fidelity Nasdaq Composite Index ETFONEQ81.24万0.01%109.4亿 USD0.21%US$107.81+0.63%
iShares International Country Rotation Active ETFCORO40.41万0.00%131.46亿 USD1.06%US$36.17+0.61%
Virtus Biotech Clinical Trials ETFBBC32.15万0.78%4099.65万 USD0.65%US$44.1456+2.08%
Fidelity Disruptive Medicine ETFFMED22.1万0.45%5231万 USD0.50%US$31.4003+2.73%iShares Biotechnology ETFIBBiShares Core MSCI EAFE ETFIEFAiShares MSCI EAFE Small-Cap ETFSCZiShares MSCI Netherlands ETFEWNFidelity Nasdaq Composite Index ETFONEQiShares International Country Rotation Active ETFCOROVirtus Biotech Clinical Trials ETFBBCFidelity Disruptive Medicine ETFFMEDAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
